Related Experiment Video
Updated: Mar 16, 2026
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Is the Mouse a Good Model of Human PPARγ-Related Metabolic Diseases?
Attila Pap1, Ixchelt Cuaranta-Monroy2, Matthew Peloquin3
1Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen H-4012, Hungary. papa@med.unideb.hu.
Abstract:
With the increasing number of patients affected with metabolic diseases such as type 2 diabetes, obesity, atherosclerosis and insulin resistance, academic researchers and pharmaceutical companies are eager to better understand metabolic syndrome and develop new drugs for its treatment. Many studies have focused on the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ), which plays a crucial role in adipogenesis and lipid metabolism. These studies have been able to connect this transcription factor to several human metabolic diseases. Due to obvious limitations concerning experimentation in humans, animal models-mainly mouse models-have been generated to investigate the role of PPARγ in different tissues. This review focuses on the metabolic features of human and mouse PPARγ-related diseases and the utility of the mouse as a model.
Insights
Researchers explore the role of peroxisome proliferator-activated receptor gamma (PPARγ) in metabolic diseases like type 2 diabetes. Mouse models are crucial for studying PPARγ
Area of Science:
- Metabolic research
- Molecular biology
- Genetics
Background:
- Increasing prevalence of metabolic diseases like type 2 diabetes, obesity, and insulin resistance.
- Focus on the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) due to its role in adipogenesis and lipid metabolism.
- Established link between PPARγ and various human metabolic disorders.
Purpose of the Study:
- To review the metabolic characteristics of human and mouse PPARγ-related diseases.
- To evaluate the utility of mouse models in understanding PPARγ function in metabolic syndrome.
- To inform the development of new therapeutic strategies for metabolic diseases.
Main Methods:
- Literature review of studies on PPARγ and metabolic diseases.
- Comparative analysis of metabolic phenotypes in human and mouse models.
- Examination of genetic and molecular mechanisms involving PPARγ.
Main Results:
- PPARγ is a key regulator of adipogenesis and lipid metabolism.
- Dysregulation of PPARγ is implicated in human metabolic diseases.
- Mouse models exhibit conserved and distinct metabolic features compared to human PPARγ-related conditions.
Conclusions:
- PPARγ is a critical target for metabolic disease research and drug development.
- Mouse models provide valuable insights into PPARγ's role but require careful interpretation.
- Further research is needed to fully elucidate PPARγ's complex functions in metabolism.
